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Background: To investigate genes differentially expressed in peripheral blood cells (PBCs) from patients with
coronary arterial disease (CAD) under double anti-platelet therapy.
Methods: Twenty-six CAD patients that were submitted to percutaneous coronary intervention (PCI) were
selected to participate in this study. These patients took 100 mg/day of acetylsalicylic acid (ASA) and 75 mg/day
of clopidogrel. Blood samples were collected before PCI to evaluate platelet reactivity using VerifyNow ASA and
P2Y12 assays (Accumetrics). The patients were stratiﬁed into 4 quartiles based on ASA reaction units (ARUs) and
P2Y12 reaction units (PRUs). Quartile 1 (Q1) patients were classiﬁed as responders and quartile 4 (Q4) patients
as non-responders. Global mRNA expression from Q1 to Q4 was analyzed by microarray using the GeneChip
Exon 1.0 ST array (Affymetrix) and was conﬁrmed by RT-qPCR.
Results: Patients with ARU or PRU values within the ﬁrst quartile (Q1, ARU b 390 and PRU b 151) were considered
responders, while those who had ARU or PRU within the fourth quartile (Q4, ARU N 467 and PRU N 260) were
considered nonresponders. The risk factors associated for CAD showed expected frequencies and no difference
was found between Q1 and Q4. Microarray analysis identiﬁed 117 genes differentially expressed for ASA and 29
for clopidogrel between Q1 and Q4 groups (p b 0.01, FC N 1.2).
Conclusion: The variation in response to ASAmay be relatedwith an increased expression of IGF1 and IGF1R, as well
as a response to clopidogrel can be affected by pharmacokinetic change related to the reverse transport pathway
by increased expression of ABCC3.© 2013 Elsevier B.V. All rights reserved.1. Introduction
Anti-platelet therapy is the most important pharmacologic interven-
tion to prevent recurrent thrombosis and arterial occlusion progression
of coronary arterial disease (CAD) in patients after percutaneous coronary
intervention (PCI) [1]. Acetylsalicylic acid (ASA), most common anti-
platelet drug, inhibits cyclooxygenase-1 which converts arachidonic
acid into tromboxano A2 [2]. ASA is rapidly hydrolyzed, in a half-life of
20 min, to form the active metabolite salicylic acid (SA) [3]. Clopidogrel
inhibits the P2Y12 adenosine diphosphate receptor (P2RY12) in platelets,
blocking intracellular cAMP formation by endothelial-derived prostaglan-
dins [4]. Clopidogrel is a prodrug that requires hepatic biotransformationool of Pharmaceutical Sciences,
Prof. Lineu Prestes, 580, B-17,
fax: +55 11 3813 2197.
rights reserved.by cytochrome P450 enzymes to be active, in order to produce its effects
[4].
Despite of the knowledge about antiaggregation drugs used in treat-
ment of CAD patients, many questions about patient's response remain
to be answered [5]. Some evidences showed a signiﬁcant association
between nonresponse to ASA or clopidogrel and increase of death by
myocardium infarction or stroke [6].
Lack of response to antiaggregation treatment may be associated
with interindividual variability related to factors such as gender, age,
smoking, interaction with other drugs, and genetic proﬁle [7,8]. These
factors could change the bioavailability of the drug altering the pharma-
cokinetics (absorption, biotransformation and excretion) or changing
the mechanisms of action (pharmacodynamics) and hence deﬁning an
inadequate therapeutic response [9].
Pharmacogenomic studies have investigated the relationship be-
tween variability of drug response andmRNAexpression proﬁle.Waehre
et al. investigated the effects of clopidogrel on mRNA expression in
10 A.D. Luchessi et al. / Clinica Chimica Acta 425 (2013) 9–17peripheral bloodmononuclear cells of patients with CAD of RANTES che-
mokine and macrophage inﬂammatory peptide (MIP)-1beta (MIP-1b)
genes in T-cells [10]. These authors found an increase in the gene expres-
sion of RANTES andMIP-1b in patients treated with clopidogrel. Despite
the important contribution of this study few genes were tested.
In order to conduct a large scale analysis a high performance
technique has been used for global mRNA expression studies
[11,12]. Kondkar et al. used microarray technology to screen the
human platelet transcriptome. In this study an increase in the content
of mRNA for VAMP8/endobrevinwas veriﬁed, in association with platelet
hyperreactivity when stimulated with agonists such as ADP and arachi-
donic acid [13]. It is also important to consider that the platelet–leukocyte
interactions are involved in platelet activation and alsowith the response
of clopidogrel and ASA treatment [14,15]. In addition the dynamic and
interactive properties of blood give rise to the possibility that subtle
changes occurring within the body, such as changes in association with
a disease process or in response to drugs, may leave ‘footprints’ in
blood [16]. For this reason, the differential analysis of transcripts content
in peripheral blood cells (PBCs) can be applied for diagnosis, prognosis
and therapeutic response [17].
Considering the potential application of pharmacogenomics as a new
strategy based in the characterization of existing variability in expression
proﬁle and its association with the response to antiaggregation, this
study focused on the global gene expression proﬁle of peripheral blood
cells as a target to drive an individualized therapeutic approach in
patients with CAD. This is an important strategy to establish an efﬁcient
drug treatment.
2. Materials and methods
2.1. Subjects and clinical protocol
Twenty six male patients with CAD were recruited from Hospital
do Meixoeiro (Vigo, Spain). CAD patients were treated with ASA
(100 mg/day) and clopidogrel (75 mg/day) for more than ﬁve days
plus other medications such as beta blockers, nitrates, statin and pump
proton inhibitors. The last doses of ASA and clopidogrel were takenwith-
in 24 h before undergoing percutaneous coronary intervention (PCI).
Exclusion criteria were: primary PCI; high bleeding risk; chronic
renal failure; use of thienopyridine, glycoprotein IIb/IIIa inhibitor and
warfarin; and allergic reaction or contraindication to ASA or clopidogrel.
The study protocol was approved by the hospital's medical ethics
committee, and informed consent was obtained from each patient.
Information on age, systolic and diastolic pressures, body mass index
(BMI), diabetes, dyslipidemia, tobacco smoking, family history of CAD
and time from last dose of clopidogrel and acetylsalicylic acid (TLDC
and TLDA, respectively) was recorded. Blood samples were drawn pre-
vious to PCI to evaluate platelet aggregation and global mRNA expres-
sion analysis.
2.2. Inhibition of platelet aggregation assays
Inhibition of platelet aggregation was evaluated before PCI by
turbidimetric optical detection using the VerifyNow ASA and P2RY12
assays (Accumetrics, San Diego, USA), as described previously [18]. In
brief, 2.0 mL of citrated-blood was transferred into standard cartridges
containing ﬁbrinogen-coatedmicro beads. Arachidonic acid and adeno-
sine diphosphate were added into the cartridges to evaluate inhibition
of platelet aggregation by ASA and clopidogrel, respectively. The results
were expressed as ASA reaction units (ARU) and P2RY12 reaction units
(PRU), respectively.
The platelet responses to clopidogrel (PRU) and ASA (ARU) values
were categorized in quartiles. Quartile 1 (Q1) represents responder
patients group and quartile 4 (Q4), represents non-responder patients
group.2.3. Global mRNA expression analysis by DNA microarray technology
Whole blood from 26 CAD patients was drawn into PAXgene tubes
(PreAnalytiX, Hombrechtikon, CH) that allows RNA extraction from total
peripheral blood cell including mononuclear and polymorphonuclear
cells. RNA extraction was performed using PAXgene Blood RNA kits
and QIAcube automated system (Qiagen, Valencia, USA). Total RNA
was evaluated using a RNA 6000 Nano LabChip kit in 2100 Bioanalyzer
(Agilent Technologies, Germany). Samples with RNA Integrity Number
(RIN) lower than 7 were excluded.
RNA was transcribed into cDNA with a double reverse transcriptase-
PCR technique. Afterwards, in vitro transcription of cDNAwas performed
to generate biotin-labeled cRNA for subsequent hybridization on
GeneChip Human Exon 1.0 ST Array (Affymetrix, Santa Clara, USA).
Hybridized cRNA was stained with streptavidin–phycoerythrin and
microarray chips were scanned using a GeneArray Scanner (Affymetrix,
Santa Clara, USA) at the 488 nm excitation wavelength.
Microarray data were described in accordance to Minimum
Information About a Microarray Experiment (MIAME) guidelines
and were deposited in the Gene Expression Omnibus (GEO) dataset
(http://www.ncbi.nlm.nih.gov/projects/geo/) as GSE32226 series. After
robust multiarray average (RMA) normalization procedure the genes
were considered differently expressed for p-values b 0.01 of fold-
changes (FC) N 1.2, in order to capture a signiﬁcant number of candidate
genes to be evaluated by RT-qPCR [19]. Unsupervised principal compo-
nent analyses (PCA) was performed using Partek® Genomic Suite
(Partek Inc., St. Louis, USA). Four PCA plots were proposed to conﬁrm
the role of the identiﬁed genes, two plots were constructed with gene
differently expressed between quartiles of ASA and clopidogrel re-
sponses, and other twowith hundred randomly selected gene set results
to conﬁrm the role of the identiﬁed genes. The selected genes were
further analyzed using the tool Ingenuity Path Analysis (IPA) of the
Ingenuity® Systems software v. 8.4 (Ingenuity Systems, Redwood City,
USA). IPA is an internet-accessible database in which the interaction
between genes andgene products is stored based on known interactions
previously described. It allows functional interpretation in terms of
biological process, molecular interactions and disease processes.2.4. Differential mRNA expression analysis by RT-qPCR
Genes differentially expressed (GDE) according to the microarray
data analysis were evaluated by reverse transcription quantitative PCR
(RT-qPCR). The selection criteria of target genes were: (1) genes previ-
ously associated with CVD, with signiﬁcant differences in expression at
ﬁrst quartile (Q1) of clopidogrel or ASA response compared with the
fourth quartile (Q4) (p b 0.01, FC ≥ 1.2); (2) genes with signiﬁcant dif-
ferences in expression that are directly or indirectly interconnected
using the Ingenuity Pathway Analysis (IPA).
RNA sample was converted to cDNA using a High-Capacity cDNA
reverse transcription kit (Applied Biosystems, Foster City, USA). The
cDNAwas ampliﬁed using 90 nM of speciﬁc primers, 250 nM of probes
(inventoried TaqMan® gene expression assays by Applied Biosystems)
and 1× Gene Expression Master Mix (Applied Biosystems), with the
following cycling parameters: 40 cycles at 95 °C for 15 s and at 60 °C
for 1 min using 7500 Real-Time PCR System (Applied Biosystems).
The content of glyceraldehyde-3-phosphate dehydrogenase gene
(GAPDH) transcript was used as reference, by presenting the average
logarithmic intensity of content close to target transcripts and a low
coefﬁcient of variation among all genes studied, through the analysis
of data from microarray experiments.
Sample cycle quantiﬁcation (Cq) values were determined from
plots of normalized ﬂuorescence versus number of PCR cycles during
exponential ampliﬁcation by Sequence Detection Software v. 2.0.1
(Applied Biosystems). The relative quantiﬁcation value of each target
transcript was analyzed using a comparative Cq method [20].
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11A.D. Luchessi et al. / Clinica Chimica Acta 425 (2013) 9–17Experimental validation was performed by Spearman's correla-
tions between results of microarray and RT-qPCR experiments [21].
The p-values were obtained from Fisher's z-transformation using
Partek® Genomic Suite software (Partek Inc., St. Louis, USA). Gene
expression also was considered validated when FC value of microarray
and RT-qPCR is shown in the same direction of change, over or down
expression.
2.5. Statistical analysis
Continuous variables are presented as mean and standard deviation
(SD) and were compared using Mann–Whitney U test for unpaired
data. Categorical variables are presented as absolute number and fre-
quency and were compared by Fisher's Exact Test (two-tailed tests).
Analysis of clinical variables was performed using SPSS 15.0 software
(SPSS, Chicago, USA) and a p-value b 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Clinical data and platelet response to ASA and clopidogrel
Table 1 shows clinical data and response to anti-platelet drugs.
High frequency of dyslipidemia (88%) and arterial hypertension (62%)
was observed in DAC patients. The mean values of time from the last
oral dose (TLD) of ASA and clopidogrel were 13 ± 8 and 11 ± 9 h,
respectively.
As commented previously, the anti-platelet response patients were
categorized in quartiles of ARU or PRU values (Table 1). Comparison of
mean ARU and PRU values between quartiles showed that Q1 is signiﬁ-
cantly different from Q4 (p b 0.001). Patients with ARU or PRU values
within the ﬁrst quartile (Q1, ARU b 390 or PRU b 151) were considered
responders, while those who had ARU or PRU within the fourth quartile
(Q4, ARU N 467 or PRU N 260) were considered non-responders.
Besides the differences of ARU and PRU mean values between Q1
and Q4, no other studied variable differed between quartiles of anti-
platelet response group (Table 1, p N 0.05).
3.2. Global mRNA expression results
After performing the raw microarray data, it was processed using
the Expression Console (Affymetrix) with background adjustment,
which divides the measured hybridization intensities into a back-
ground, and a signal component. All RNA samples passed the quality
control tests with a careful inspection of the scanned images, the grid
alignment. Subsequently, it was conﬁrmed that the automatic grid
alignment worked properly by using internal spikes (biotinylated B2),
which mark the outer boundary, the checkerboard structure, and the
array name.
For statistical microarray analyses we compared the extreme
values of ASA and clopidogrel response in contrast to Q1 and Q4 groups,
for each therapy response. Because the response values are determined
independently from each other, the patients were distributed randomly
between quartile responses to ASA and clopidogrel.
Using the criteria previously established (FC N 1.2, p-value b 0.01),
117 genes were differently expressed between ASA Q1 (responder)
and Q4 (non-responder). Eighty-eight genes were overexpressed and
29 (in bold) were downregulated in responder patients compared
with non-responders (Table 2). GDE were also found in response to
clopidogrel, as shown in Table 3. Among the 29 GDE, 11 genes were
overexpressed and 18 (in bold) were downregulated in clopidogrel
responder patients (Q1) in comparison with non-responders (Q4).
Results of PCA showed the capacity of these two lists of GDE, Tables 2
for ASA and 3 for clopidogrel, to categorize all patients in clusters of
quartile response of antiaggregation therapy based in log2 ratio of ex-
pression microarray value for ASA (Fig. 1a) and clopidogrel (Fig. 1c).
Table 2
Genes differently expressed between Q1 and Q4 responses to ASA.
Gene symbol RefSeq p-Value FC
KCTD21 NM_001029859 2.99E−05 1.5
SEMA3D NM_152754 6.36E−05 1.2
ATP6V1G3 NM_133326 8.23E−04 1.2
PSG9 NM_002784 9.52E−04 1.3
STOX1 NM_152709 1.21E−03 1.3
COX7A2 NM_001865 1.26E−03 1.4
ENG NM_000118 1.38E−03 1.2
SNAP23 NM_003825 1.59E−03 −1.4
C4orf31 NM_024574 1.65E−03 1.2
ARHGEF5L NM_001003702 1.84E−03 1.4
IK NM_006083 1.92E−03 −3.2
C6orf146 BC039349 2.14E−03 1.2
RSF1 NM_016578 2.15E−03 −1.3
LRRC67 NM_001013626 2.15E−03 1.3
FSD1L NM_031919 2.20E−03 1.3
ZNF211 NM_006385 2.54E−03 −1.4
PQLC2 NM_001040125 2.54E−03 1.2
ECT2 NM_018098 5.63E−03 1.2
GUCA1C NM_005459 5.68E−03 1.3
THEM5 NM_182578 5.70E−03 1.3
GPR177 NM_024911 5.74E−03 −2.1
PAFAH1B2 NM_002572 5.75E−03 −1.2
ADH1B NM_000668 5.89E−03 1.2
HS3ST3B1 NM_006041 6.03E−03 −1.6
NFIA NM_001134673 6.04E−03 1.3
DDX43 NM_018665 6.06E−03 1.3
DPP10 NM_020868 6.13E−03 1.2
VANGL1 NM_138959 6.27E−03 1.3
FDPS NM_001135821 6.29E−03 1.2
OR6K3 NM_001005327 6.34E−03 1.3
CRYGC NM_020989 6.35E−03 1.3
FAM84A NM_145175 6.42E−03 1.2
A2ML1 NM_144670 6.48E−03 1.2
SNX17 NM_014748 6.51E−03 1.2
REM2 NM_173527 6.52E−03 −1.3
TNFAIP8L3 NM_207381 6.52E−03 1.2
CTD-2090I13.4 BC062736 9.60E−03 1.3
OR13C2 NM_001004481 9.67E−03 1.6
UGT2B7 NM_001074 9.68E−03 1.6
ANP32D NM_012404 2.55E−03 1.6
C4orf21 NM_001099776 2.66E−03 1.2
PRDM9 NM_020227 2.71E−03 1.3
GGH NM_003878 2.75E−03 1.3
HEATR5A NM_015473 2.79E−03 −1.5
YWHAH NM_003405 2.82E−03 −1.6
NTNG1 NM_001113226 2.92E−03 1.2
PLIN5 NM_001013706 3.36E−03 −1.6
ANAPC4 NM_013367 3.36E−03 1.6
TDGF1 NM_003212 3.59E−03 1.5
MSTO1 NM_018116 3.69E−03 1.3
EPGN NM_001013442 3.83E−03 1.2
OR5M8 NM_001005282 3.86E−03 1.3
LOC554203 NR_024582 3.88E−03 1.3
NEUROD6 NM_022728 3.99E−03 1.3
ZNF770 NM_014106 4.03E−03 1.2
FBLN2 NM_001004019 4.11E−03 −1.4
FAM13A NM_014883 6.54E−03 1.2
TRAIP NM_005879 6.63E−03 1.3
SPC25 NM_020675 6.70E−03 1.3
FLJ42875 NR_015440 6.72E−03 1.2
DDAH1 NM_012137 6.77E−03 1.2
MSH4 NM_002440 6.82E−03 1.3
PMCHL2 NR_003922 6.86E−03 1.3
IL2RA NM_000417 6.98E−03 −1.7
PRDX3 NM_006793 9.69E−03 −1.3
GAFA3 AF220235 7.05E−03 1.3
WNT9A NM_003395 7.09E−03 1.2
ARPM1 NM_032487 7.20E−03 1.3
FAM47E NM_001136570 7.22E−03 1.2
C14orf101 NM_017799 7.45E−03 −1.4
C4B NM_001002029 7.50E−03 1.3
ANKRD7 NM_019644 7.51E−03 1.2
DPY19L3 NM_207325 7.56E−03 −1.4
IL1A NM_000575 7.57E−03 1.5
RARRES1 NM_206963 7.76E−03 1.2
Table 2 (continued)
Gene symbol RefSeq p-Value FC
ZC3HAV1L BC020784 7.76E−03 1.4
ST20 NM_001100879 7.88E−03 −2.0
CENPE NM_001813 7.95E−03 1.2
PSG1 NM_006905 4.16E−03 1.3
PDC NM_002597 4.22E−03 1.3
OR2B2 NM_033057 4.31E−03 1.3
HSPA1A NM_005345 4.45E−03 −2.1
RNF212 NM_001131034 4.61E−03 1.2
DEPDC1 NM_001114120 4.66E−03 1.3
NKAIN3 NM_173688 4.74E−03 1.3
KCNMB1 NM_004137 4.97E−03 1.4
PAM NM_000919 5.05E−03 −1.7
CWH43 NM_025087 5.19E−03 1.3
ASPM NM_018136 5.33E−03 1.2
TECRL NM_001010874 5.34E−03 1.2
ZNF789 NM_213603 5.34E−03 1.3
APH1B NM_031301 5.38E−03 −1.4
RFPL1 NM_021026 5.42E−03 1.3
C1QTNF2 NM_031908 5.52E−03 1.2
DIAPH3 NM_001042517 5.54E−03 1.2
NCRNA00116 BC064430 7.83E−03 1.2
AGBL3 NM_178563 7.83E−03 1.4
ADD3 NM_016824 8.38E−03 −1.5
TPD52L2 NM_199360 8.38E−03 −1.4
IGF1R NM_000875 8.51E−03 −1.9
CCL26 NM_006072 8.68E−03 1.3
AKTIP NM_001012398 8.68E−03 −1.6
SSU72 NM_014188 8.82E−03 −1.5
FGG NM_021870 7.98E−03 1.3
USP6NL NM_014688 8.32E−03 −1.4
CXCR7 NM_020311 8.84E−03 1.3
ST3GAL4 NM_006278 8.94E−03 −1.3
UGT2B10 NM_001075 8.99E−03 1.4
DNAH6 NM_001370 9.00E−03 1.2
UNQ3104 AY358109 9.02E−03 −1.5
SLCO6A1 NM_173488 9.06E−03 1.3
CCL8 NM_005623 9.10E−03 1.3
FLJ32955 AK057517 9.73E−03 1.2
PSIP1 NM_033222 9.77E−03 −1.4
GPR111 NM_153839 9.84E−03 1.3
C21orf74 AY077696 9.85E−03 1.2
RP1 NM_006269 9.89E−03 1.2
FC, Fold-Change. In bold genes down-regulated in Q4.
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the randomly selected 100 genes (Fig. 1b and d), it is possible to verify
the predictive value of the differentially expressed genes, conﬁrming
the role of the identiﬁed genes listed in Tables 2 and 3.3.3. Pathway analysis of genes differently expressed
The relationship among GDE in response to anti-platelet drugs
was evaluated by IPA. As shown in Fig. 2, 33 genes (in white), not
found as differently expressed in this experiment, were directly or
indirectly related to 18 GDE. In response to ASA 11 genes were found
up-regulated (dark gray) and 7 down-regulated (gray). Among the 51
genes from Fig. 2, four genes (HNF1A, IL1A, NFkB and TP53) seem to
be a central role by having more than seven indicating relationships
(continuous or dotted arrows).
The HNF1A, was related to UGT2B7, SNX17 and NFIA that showed
down-regulated and PAFAH1B2, RSF1 and IGF1R that showed up-
regulated in non-responder group (Q4) (p b 0.01). Additionally, IGF1R
(up-regulated in Q4) is related with PTGS1 and PTGS2 genes, which are
principal targets of ASA. The, IL1A was linked to IK and IL2RA (both,
down-regulated) and CCL8, UGT and UGT2B1 (up-regulated) (p b 0.01).
In addition, IL1A is related to TP53, that makes linkage with other genes
that showed up-regulated, such as IGF1R, HSPA1A and SNP23 (p b 0.01)
and down-regulated such as ENG and CENPE (p b 0.01) in non-
responder group (Q4).
Table 3
Genes differently expressed between Q1 and Q4 response to clopidogrel.
Gene symbol RefSeq p-Value FC
ABO NM_020469 1.80E−04 −1.2
CYS1 NM_001037160 2.60E−04 1.4
SULT1A1 NM_177536 8.72E−04 −1.2
INSL3 NM_005543 1.90E−03 −1.3
ST13 NM_003932 2.14E−03 1.4
C19orf55 BC110893 2.40E−03 −1.2
C1orf85 NM_144580 2.51E−03 1.7
FAM20B NM_014864 2.77E−03 1.3
NFXL1 NM_152995 4.13E−03 2.2
HIST1H2BJ NM_021058 4.72E−03 1.3
MRPS33 NM_016071 5.23E−03 1.3
CA2 NM_000067 5.57E−03 1.8
TFDP2 NM_006286 5.63E−03 1.6
UBE2F NM_080678 5.70E−03 2.1
TRY6 NR_001296 5.92E−03 −1.3
NOP56 NR_027700 6.33E−03 1.4
MBP NM_001025081 6.61E−03 −1.3
GUCA2B NM_007102 7.23E−03 −1.2
MKRN1 NM_013446 7.26E−03 1.6
UBTD1 NM_024954 7.56E−03 −1.2
ELK4 NM_001973 7.58E−03 1.3
IGHMBP2 NM_002180 7.61E−03 1.7
ENDOD1 NM_015036 7.67E−03 1.3
ABCC3 NM_003786 8.19E−03 1.2
SPRR1A NM_005987 8.47E−03 −1.4
USP45 NM_001080481 8.47E−03 1.2
LY6H NM_001135655 8.53E−03 −1.2
ORAI3 NM_152288 9.30E−03 −1.2
HECTD3 NM_024602 9.54E−03 1.3
FC, Fold-Change. In bold genes down-regulated in Q4.
Fig. 1. Two-dimensional principal component analysis of the genes differentially expressed for
expressionmicroarray value of gene differentially expressed for ASA response (Table 2). Panel (
response. Panel (c) shows the expression microarray value of gene differentially expressed for
domly selected gene for set results for clopidogrel response. In black, Q1 (responder patients),
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to responder (Q1) and non-responder (Q4) for clopidogrel therapy
(Fig. 3). Nine GDE related to transcription factorHNF4Awere shown. In-
deed, MBP and SULT1A1 genes as down-regulated (gray) and MKRN1,
UBE2F, TFDP2, ABCC3, NOP56, CA2 and ST13 as up-regulated (dark
gray) in non-responder group compared to responders (p b 0.01). In
this same pathway other 14 genes, not found as differentially expressed
in the microarray experiment (white), were related as participants
in pharmacokinetics or pharmacodynamics of clopidogrel, such as
CYP2C9, CYP2B6, CES1 and P2RY12 (Fig. 3).
3.4. Experimental validation of differential gene expression by RT-qPCR
Seven genes: RSF1, NFIA, IL2RA, IL1A, IK, IGF1R and CCL8 and eight
genes: UBE2F, TFDP2, SULT1A1, ST13, MKRN1, MBP, CA2 and ABCC3,
were considered validated for ASA and clopidogrel expression analyses
respectively, to show the same proﬁle of microarray and RT-qPCR
fold-change (Fig. 4). Additionally, Spearman's correlationbetween inten-
sity value of microarray results and relative expression value obtained
from RT-qPCR, shows moderate to strong correlation between the tech-
niques for gene NFIA and IGF1R genes in response to ASA (r ≥ 0.60,
p b 0.05) and CA2, MKRN1, ABCC3 and MBP in response to clopidogrel
(r ≥ 0.42, p b 0.05).
4. Discussion
This study, for the ﬁrst time, provides a genome-wide gene expres-
sion proﬁle of PBC from clinically intervened patients of CAD in responsequartiles of patients' responder. Each spot represents a patient sample. Panel (a) shows the
b) shows the expressionmicroarray value of randomly selected gene for set results for ASA
clopidogrel response (Table 3). Panel (d) shows the expression microarray value of ran-
dark gray, Q2; gray, Q3, and white, Q4 (non-responder patients).
Fig. 2. Schematic representation of the direct and indirect relationships of the differently expressed genes in responder and nonresponder patients of ASA. In dark gray, representing
the genes with signiﬁcantly low expression; in gray, genes with signiﬁcantly increased expression; white, genes that participate in the network; however, expression was not
signiﬁcantly different; continuous tracings, relationship with signalization pathways; continuous arrows, direct relationship among the genes; dotted arrows, indirect relationship
among the genes.
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dual antiplatelet regimen with ASA and clopidogrel has been shown to
signiﬁcantly reduce the cardiovascular events. However, stent thrombo-
sis, a major adverse cardiovascular event, can also occur in patients tak-
ing ASA and clopidogrel [22]. This suggests that platelet aggregation
nonresponsiveness to ASA or clopidogrel is themain cause of the throm-
botic event.
Although there is no standard deﬁnition of nonresponsiveness to
dual antiplatelet drugs, it is important to identify the patients with
these conditions. The patients were classiﬁed according to quartile of
response to antiaggregation agents, as was described by other studies
[18,23]. Therefore, our results established that 25% of the patients
in upper quartiles were considered as non-responders for ASA or
clopidogrel. Different studies described an incidence of non-responders
ranging from 5.9% to 24% using a cutoff value upper to 525 ARU or 349
PRU for ASA and clopidogrel, respectively [24]. Although different ways
to classify patients according to response to antiaggregation agents
exist, many clinical studies have demonstrated the useful categorization
of response by quartile. Skoric et al. [25] demonstrated that thrombolysis
in myocardial infarction score (TIMI) is associated with quartiles of
aggregation response. They have also found a signiﬁcantly higher
frequency of TIMI-2 and -3 among those with low values of platelet
aggregation.
Tsukahara et al. [26] showed that low-responders to dual antiplatelet
therapy were more likely to have adverse cardiac events, in contrast,
high-responders had a higher rate of bleeding complications with no
reduction in adverse cardiac events as compared with other quartiles
of responders, independent of the risk factors associated with CAD. Our
results show the same relationship of risk factors for CAD. Hypertension,dyslipidemia, diabetes, obesity, smoking and the presence of family his-
tory of CAD showed expected frequencies andno differencewas found in
the group of responders and non-responders to ASA and clopidogrel;
these data were similar to other previous studies [23,27–29].
Our study showed that a group of genes that are differentially
expressed according to the response of ASA or clopidogrel exists,
and that when a principal component analysis is used it was possible
to categorize the patients in relation to quartiles of responses consid-
ering the mRNA expression of these genes founded as differentially
expressed.
In our results, the HNF1A mRNA was revealed. The protein coded
by this transcript has an important function as transcription factor
involved with diverse metabolic functions in the liver, pancreatic
islets, kidneys, and intestines [30].
The HNF1A was found with a central gene in our results. Interest-
ingly, it showed no difference in the expression, that can have distinct
regulation mechanisms or tissue-speciﬁc expression for all nuclear
factors [31]. Its expression may be unchanged in blood cells, while
its expression in hepatocytes may be differentially regulated, creating
the difference in gene expression in other tissues. Conde-Vancells et
al. identiﬁed a signiﬁcant number of proteins previously described
among exosomes derived from other cell types as well as proteins
involved in the metabolism of lipoproteins, endogenous compounds
and xenobiotics, not previously described in exosomes [32].
Nuclear factor IA (NFIA), linked to HNF1A in a pathway, showed a
decreased mRNA expression in non-responder group, and this activity
can be regulating the process of gene transcription [33].
OtherHNF1A-linked gene involvedwith this study is the insulin-like
growth factor 1 receptor (IGF1R) responsible for intracellular signaling
Fig. 3. Schematic representation of the direct and indirect relationships of the differently expressed genes in responder and nonresponder patients of clopidogrel. In dark gray,
representing the genes with signiﬁcantly low expression; in gray, genes with signiﬁcantly increased expression; white, genes that participate in the network; however, expression
was not signiﬁcantly different; continuous tracings, relationship with signalization pathways; continuous arrows, direct relationship among the genes; dotted arrows, indirect
relationship among the genes.
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content of IGF1R mRNA was higher in patients characterized as
non-responders. The gene IGF1R is the main representative in the
gene network of different expression related with antiplatelet ASA
therapy, since both insulin-like growth factor 1 (IGF1) and receptor
(IGFR1) itself have been detected in platelets [35,36], and an increase
of IGF1 mRNA in blood has also been correlated with increased risk of
developing cardiovascular disease [37,38].
It has been shown that IGF1R and IGF1 can enhance platelet
aggregation contributing to the ampliﬁcation of platelet response
and pathogenesis of cardiovascular disease [39]. Our results contrib-
ute to the relationship between the IGF1R and IGF1 and platelet
aggregation, since the increased expression of IGF1R is associated
with non-responder patients for ASA antiplatelet therapy.
The analysis of genes differentially expressed for clopidogrel re-
sponse showed the hepatocyte nuclear factor 4A (HNF4A) as central in
the gene network established, which has genetic variants associatedwith diabetes type MODY1 [40]. This factor regulates the transcription
of multiple genes involved in glucose, cholesterol and fatty acid
metabolism; however, there is no account of the function of this gene
in peripheral blood cells [41].
The gene ABC-type efﬂux subfamily C member 3 (ABCC3) is one of
the genes whose expression is controlled by HNF4A and its expression
is increased in non-responder individuals to clopidogrel [18]. The
regulation of ABCC3 gene by HNF4A was shown by Lu et al., who
described that HNF4A knockout mice have lacked the expression of
efﬂux transporters in the liver, including ABCC3 gene [42].
Bohan et al., showed that induced expression of ABCC3 exerts a
hepatoprotective effect in cholestasis, suggesting that its transcrip-
tion is regulated by nuclear receptor subfamily 5 group A member 2
(NR5A2). The NR5A2 is a transcription factor present in hepatocytes
and its activity is dependent of the signaling pathway of tumor necro-
sis factor alpha (TNFalpha) [43]. However, the exact mechanism that
involves regulation of ABCC3 mRNA expression in blood cells and if
Fig. 4. Technical validation by comparison of fold change values between microarray and real time PCR data. Gray bars represent microarray data and black bars represent real time
PCR data. * represents a p value b 0.05 and r value between 4 and 0.7 for Spearman's correlation analysis.
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elucidated.
Other gene associated with the same network related to HNF4A is
Makorin ring ﬁnger protein-1 (MKRN1). This gene is involved to the
control of transcription mediated by RNA polymerase II [44].
K. Amiyama et al. have demonstrated the fundamental role of
HNF4A in the gene expression of drug metabolizing enzymes such
as CYP2C9 in human hepatocytes; this relationship was also found
in our study [45]. CYP2C9 gene is directly related to clopidogrel as
a major contributor to the formation of its active metabolite [46],
although its expression was not signiﬁcantly different between both
groups of responders, when we analyzed the blood cells.
After the discussion of how genes differentially expressed can
affect the antiplatelet therapeutic response, other question emerges.
What cell type, in the PBC collection, gene expression changes?
In fact, cannot be sure in which cells the alteration of expression
occurred. Wingrove et al. demonstrated that a large discovery study
using mRNA from whole blood cells was replicated by other studies
that used only mononuclear cells and the authors showed the results
with PBC had a better proﬁle of gene expression in patients undergo-
ing angiography [47]. Furthermore further functional experiments
with other models must be conducted with the purpose of evaluating
their association with the increase of death by myocardial infarction
or stroke.
In conclusion, the results from this study are suggestive that vari-
ation in platelet responses to ASA and clopidogrel is associated with
different gene expressions in PBC. Two genes can be considered the
main representatives of this relationship, HNF1A and HNF4A for ASA
and clopidogrel, respectively. These data indicate a possible relation-
ship between the expressions of peripheral blood cells with other
types of tissue such as hepatocytes. Moreover, the variation in re-
sponse to ASA may be related to the level of expression of IGF1 and
IGF1R, as well as a response to clopidogrel that can be affected by
pharmacokinetic changes related to the reverse transport pathway
of ABCC3 and metabolism of by CYP2C9.Acknowledgments
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